L. Finn, S. Markovic, and R. Joseph, Therapy for metastatic melanoma: the past, present, and future, BMC Medicine, vol.136, issue.8, p.23, 2012.
DOI : 10.1001/archsurg.136.8.950

O. Michielin and C. Hoeller, Gaining momentum: New options and opportunities for the treatment of advanced melanoma, Cancer Treatment Reviews, vol.41, issue.8, pp.660-670, 2015.
DOI : 10.1016/j.ctrv.2015.05.012

Z. Zhu, W. Liu, and V. Gotlieb, The rapidly evolving therapies for advanced melanoma???Towards immunotherapy, molecular targeted therapy, and beyond, Critical Reviews in Oncology/Hematology, vol.99, pp.91-99, 2016.
DOI : 10.1016/j.critrevonc.2015.12.002

J. Redman, G. Gibney, and M. Atkins, Advances in immunotherapy for melanoma, BMC Medicine, vol.33, issue.Suppl 3, 2016.
DOI : 10.1186/s12916-016-0571-0
URL : http://doi.org/10.1186/s12916-016-0571-0

C. Robert, L. Thomas, I. Bondarenko, O. Day, S. Weber et al., Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma, New England Journal of Medicine, vol.364, issue.26, pp.2517-2526, 2011.
DOI : 10.1056/NEJMoa1104621

P. Chapman, A. Hauschild, C. Robert, J. Haanen, P. Ascierto et al., Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation, New England Journal of Medicine, vol.364, issue.26, pp.2507-2516, 2011.
DOI : 10.1056/NEJMoa1103782

E. Riveiro-falkenbach, C. Villanueva, M. Garrido, Y. Ruano, R. García-martín et al., Intra- and Inter-Tumoral Homogeneity of BRAFV600E Mutations in Melanoma Tumors, Journal of Investigative Dermatology, vol.135, issue.12, pp.3078-3085, 2015.
DOI : 10.1038/jid.2015.229

M. Lacouture, M. Duvic, A. Hauschild, V. Prieto, C. Robert et al., Analysis of Dermatologic Events in Vemurafenib-Treated Patients With Melanoma, The Oncologist, vol.18, issue.3, pp.314-322, 2013.
DOI : 10.1634/theoncologist.2012-0333

M. Eisenhut, W. Hull, A. Mohammed, W. Mier, D. Lay et al., -(2-Diethylaminoethyl)benzamide Derivatives with High Melanoma Uptake:?? Structure???Affinity Relationships, Metabolic Fate, and Intracellular Localization, Journal of Medicinal Chemistry, vol.43, issue.21, pp.3913-3922, 2000.
DOI : 10.1021/jm991079p

J. Chezal, J. Papon, P. Labarre, C. Lartigue, M. Galmier et al., -(2-diethylaminoethyl)-4-iodobenzamide for Imaging and Targeted Radionuclide Therapy of Melanoma, Journal of Medicinal Chemistry, vol.51, issue.11, pp.3133-3144, 2008.
DOI : 10.1021/jm701424g

J. Michelot, M. Moreau, A. Veyre, J. Bonafous, F. Bacin et al., Phase II scintigraphic clinical trial of malignant melanoma and metastases with iodine-123-N-(2-diethylaminoethyl 4-iodobenzamide), J Nucl Med, vol.34, pp.1260-1266, 1993.

N. Moins, D. Incan, M. Bonafous, J. Bacin, F. Labarre et al., 123 I- N -(2-diethylaminoethyl)-2-iodobenzamide: a potential imaging agent for cutaneous melanoma staging, European Journal of Nuclear Medicine and Molecular Imaging, vol.29, issue.11, pp.1478-1484, 2002.
DOI : 10.1007/s00259-002-0971-6
URL : http://doi.org/10.1007/s00259-002-0971-6

F. Cachin, E. Miot-noirault, B. Gillet, V. Isnardi, B. Labeille et al., 123I-BZA2 as a Melanin-Targeted Radiotracer for the Identification of Melanoma Metastases: Results and Perspectives of a Multicenter Phase III Clinical Trial, Journal of Nuclear Medicine, vol.55, issue.1, pp.15-22, 2014.
DOI : 10.2967/jnumed.113.123554

L. Rbah-vidal, A. Vidal, S. Besse, F. Cachin, M. Bonnet et al., Early detection and longitudinal monitoring of experimental primary and disseminated melanoma using [18F]ICF01006, a highly promising melanoma PET tracer, European Journal of Nuclear Medicine and Molecular Imaging, vol.35, issue.9, pp.1449-1461, 2012.
DOI : 10.1007/s00259-012-2168-y

J. Joyal, J. Barrett, J. Marquis, J. Chen, S. Hillier et al., Preclinical Evaluation of an 131I-Labeled Benzamide for Targeted Radiotherapy of Metastatic Melanoma, Cancer Research, vol.70, issue.10, pp.4045-4053, 2010.
DOI : 10.1158/0008-5472.CAN-09-4414

M. Bonnet, F. Mishellany, J. Papon, A. Cayre, F. Penault-llorca et al., Anti-melanoma efficacy of internal radionuclide therapy in relation to melanin target distribution, Pigment Cell & Melanoma Research, vol.47, issue.5, pp.1-11, 2010.
DOI : 10.1111/j.1755-148X.2010.00716.x

F. Degoul, M. Borel, N. Jacquemot, S. Besse, Y. Communal et al., I-labelled melanin-targeting heteroarylcarboxamide molecule, International Journal of Cancer, vol.27, issue.5, pp.1042-1053, 2013.
DOI : 10.1002/ijc.28103
URL : https://hal.archives-ouvertes.fr/in2p3-00926259

W. Mier, C. Kratochwil, J. Hassel, F. Giesel, B. Beijer et al., Radiopharmaceutical Therapy of Patients with Metastasized Melanoma with the Melanin-Binding Benzamide 131I-BA52, Journal of Nuclear Medicine, vol.55, issue.1, pp.9-14, 2014.
DOI : 10.2967/jnumed.112.112789

A. Maisonial, E. Billaud, S. Besse, L. Rbah-vidal, J. Papon et al., Synthesis, radioiodination and in??vivo screening of novel potent iodinated and fluorinated radiotracers as melanoma imaging and therapeutic probes, European Journal of Medicinal Chemistry, vol.63, pp.840-853, 2013.
DOI : 10.1016/j.ejmech.2012.11.047

E. Billaud, L. Rbah-vidal, A. Vidal, S. Besse, S. Tarrit et al., Evaluation of Novel Fluorinated and Iodinated Radiotracers for PET Imaging and Targeted Radionuclide Therapy of Melanoma, Journal of Medicinal Chemistry, vol.56, issue.21, pp.8455-8467, 2013.
DOI : 10.1021/jm400877v

D. Denoyer, P. Labarre, J. Papon, E. Miot-noirault, M. Galmier et al., Development of a high-performance liquid chromatographic method for the determination of a new potent radioiodinated melanoma imaging and therapeutic agent, Journal of Chromatography B, vol.875, issue.2, pp.411-418, 2008.
DOI : 10.1016/j.jchromb.2008.09.021

Y. Perrot, F. Degoul, P. Auzeloux, M. Bonnet, F. Cachin et al., Internal dosimetry through GATE simulations of preclinical radiotherapy using a melanin-targeting ligand, Physics in Medicine and Biology, vol.59, issue.9, pp.2183-2198, 2014.
DOI : 10.1088/0031-9155/59/9/2183

J. Villanueva, A. Vultur, J. Lee, R. Somasundaram, M. Fukunaga-kalabis et al., Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K, Cancer Cell, vol.18, issue.6, pp.683-695, 2010.
DOI : 10.1016/j.ccr.2010.11.023

K. Smalley, Z. Eroglu, and V. Sondak, Combination Therapies for Melanoma: A New Standard of Care?, American Journal of Clinical Dermatology, vol.33, issue.Suppl, pp.99-105, 2016.
DOI : 10.1007/s40257-016-0174-8

A. Norain and E. Dadachova, Targeted Radionuclide Therapy of Melanoma, Seminars in Nuclear Medicine, vol.46, issue.3, pp.250-259, 2016.
DOI : 10.1053/j.semnuclmed.2015.12.005

C. Viallard, Y. Perrot, Z. Boudhraa, E. Jouberton, E. Miot-noirault et al., [ 123 I]ICF01012 melanoma imaging and [ 131 I]ICF01012 dosimetry allow adapted internal targeted radiotherapy in preclinical melanoma models, Eur J Dermatol, vol.25, pp.29-35, 2015.

C. Viallard, J. Chezal, F. Mishellany, I. Ranchon-cole, B. Pereira et al., Targeting DNA repair by coDbait enhances melanoma targeted radionuclide therapy, Oncotarget, vol.7, pp.12927-12936, 2016.

M. Bonnet-duquennoy, J. Papon, F. Mishellany, P. Labarre, J. Guerquin-kern et al., I labelled potential agent, International Journal of Cancer, vol.27, issue.3, pp.708-716, 2009.
DOI : 10.1002/ijc.24413

S. Thompson, B. Ballard, Z. Jiang, E. Revskaya, N. Sisay et al., 166Ho and 90Y labeled 6D2 monoclonal antibody for targeted radiotherapy of melanoma: Comparison with 188Re radiolabel, Nuclear Medicine and Biology, vol.41, issue.3, pp.276-281, 2014.
DOI : 10.1016/j.nucmedbio.2013.12.015

C. Durairaj, J. Chastain, and U. Kompella, Intraocular distribution of melanin in human, monkey, rabbit, minipig and dog eyes, Experimental Eye Research, vol.98, pp.23-27, 2012.
DOI : 10.1016/j.exer.2012.03.004

D. Dimasi, A. Hewitt, K. Kagame, S. Ruvama, L. Tindyebwa et al., Ethnic and Mouse Strain Differences in Central Corneal Thickness and Association with Pigmentation Phenotype, PLoS ONE, vol.299, issue.8, 2011.
DOI : 10.1371/journal.pone.0022103.s001
URL : http://doi.org/10.1371/journal.pone.0022103